PAM
DNTH icon

Panagora Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Panagora Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-35
Closed -$6K – 1898
2021
Q2 		$6K Buy
+35
New +$6.43K ﹤0.01% 2424
2020
Q4 		– Sell
-184
Closed -$20K – 2832
2020
Q3 		$20K Buy
+184
New +$21.8K ﹤0.01% 2205

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Panagora Asset Management's DNTH Position: Q3 2021 in Review

Panagora Asset Management sold out of Dianthus Therapeutics (DNTH) in Q3 2021, closing a stake of 35 shares — an estimated $6K sold.

Panagora Asset Management first reported a position in DNTH in Q3 2020 and held it in 2 quarters. The position peaked at $20K in Q3 2020. 93 funds tracked by Wall St. Rank hold DNTH as of Q3 2021.

  • Panagora Asset Management reported no remaining Dianthus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Panagora Asset Management sold 35 Dianthus Therapeutics shares in Q3 2021, an estimated $6K.
  • Panagora Asset Management first reported a position in Dianthus Therapeutics in Q3 2020 and held it in 2 quarters.
  • Panagora Asset Management's Dianthus Therapeutics position peaked at $20K in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.